Opinion

Video

Bladder Cancer: Treatment Options and Managing Adverse Effects

Author(s):

Axel Merseburger, MD, PhD,M. Carmen Mir, MD, PhD

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

Current Time 0:00
Duration 6:17
Loaded: 2.61%
Stream Type LIVE
Remaining Time 6:17
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
    Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
    Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
    Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
    Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
    Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
    Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
    How recombinant BCG could ease strain of supply issues
    Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
    Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
    John Taylor, III, MD, on novel options in NMIBC
    John Taylor, III, MD, on novel options in NMIBC
    Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
    Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
    3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
    What a long-term study of patients undergoing RARC reveals about upstaging
    Sima Porten, MD, on the increased risk of bladder cancer among firefighters
    Sima Porten, MD, on the increased risk of bladder cancer among firefighters
    Jason Hafron, MD, predicts coming advancements in bladder cancer
    Jason Hafron, MD, predicts coming advancements in bladder cancer
    Related Content
    What urologists can expect in Q2 of 2025
    April 7th 2025

    What urologists can expect in Q2 of 2025

    Hannah Clarke Benjamin P. Saylor
    A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
    Dr. Schwen on focal therapies for prostate cancer
    January 11th 2024

    Dr. Schwen on focal therapies for prostate cancer

    Cleveland Clinic
    Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
    FDA updates in urology: March 2025
    April 1st 2025

    FDA updates in urology: March 2025

    Hannah Clarke
    A recap of the FDA submissions and regulatory decisions in urology from March 2025.
    medical depiction of bladder cancer
    May 31st 2023

    Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

    Urology Times staff
    In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
    FDA approves durvalumab/chemo for muscle–invasive bladder cancer
    March 28th 2025

    FDA approves durvalumab/chemo for muscle–invasive bladder cancer

    Hannah Clarke
    The approval is supported by results from the phase 3 NIAGARA trial.
    RAG-01 elicits complete responses in NMIBC
    March 26th 2025

    RAG-01 elicits complete responses in NMIBC

    Hannah Clarke
    "The striking CR rates observed in these early cohorts are highly encouraging, particularly for BCG-unresponsive NMIBC patients who currently have limited treatment options," says Paul D. Anderson, MBBS, FRACS.
    © 2025 MJH Life Sciences

    All rights reserved.